propafenone 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
antiarrhythmics, propafenone derivatives 2291 54063-53-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • propafenone
  • propafenone hydrochloride
  • polfenon
  • (RS)-Propafenone
  • propafenone HCl
An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity.
  • Molecular weight: 341.45
  • Formula: C21H27NO3
  • CLOGP: 3.64
  • LIPINSKI: 0
  • HAC: 4
  • HDO: 2
  • TPSA: 58.56
  • ALOGS: -4.65
  • ROTB: 11
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.30 g O
0.30 g P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.09 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0.50 % Benet LZ, Broccatelli F, Oprea TI
BA (Bioavailability) 12 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 2.20 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 16 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.04 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 2.10 hours Lombardo F, Berellini G, Obach RS

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
mdck-mdr1-bcrp-efflux MDCK-MDR1-BCRP efflux ratio 1.324 High 1
pfas-class PFAS structural alert (1 = True, 0 = False) 0
rat-kpuu-brain Rat brain Kpuu 0.076 % High 1

Approvals:

DateAgencyCompanyOrphan
Nov. 27, 1989 FDA GLAXOSMITHKLINE LLC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug interaction 243.63 19.53 193 7297 276260 90344697
Atrial fibrillation 217.58 19.53 136 7354 133475 90487482
Electrocardiogram QRS complex prolonged 180.19 19.53 52 7438 7296 90613661
Bradycardia 127.92 19.53 82 7408 83765 90537192
Sinus bradycardia 95.57 19.53 40 7450 16912 90604045
Arrhythmia 83.97 19.53 49 7441 42283 90578674
Toxicity to various agents 79.66 19.53 108 7382 287738 90333219
Completed suicide 76.62 19.53 76 7414 144982 90475975
Subarachnoid haemorrhage 67.91 19.53 32 7458 17872 90603085
Cardiac arrest 64.90 19.53 60 7430 104875 90516082
Loss of consciousness 62.35 19.53 67 7423 140171 90480786
Syncope 61.85 19.53 65 7425 132598 90488359
Enzyme induction 58.25 19.53 9 7481 53 90620904
Atrioventricular block complete 51.46 19.53 22 7468 9789 90611168
Intentional overdose 47.36 19.53 48 7442 93786 90527171
Rhabdomyolysis 45.34 19.53 36 7454 51220 90569737
Central nervous system haemorrhage 45.19 19.53 9 7481 256 90620701
Cardiogenic shock 45.04 19.53 27 7463 24441 90596516
Nodal arrhythmia 44.68 19.53 12 7478 1291 90619666
Thyroid atrophy 43.61 19.53 9 7481 307 90620650
Generalised tonic-clonic seizure 43.19 19.53 30 7460 34873 90586084
Labelled drug-drug interaction medication error 43.13 19.53 22 7468 14560 90606397
Bradyarrhythmia 41.26 19.53 13 7477 2448 90618509
Palpitations 40.33 19.53 53 7437 136675 90484282
Systolic dysfunction 40.18 19.53 12 7478 1892 90619065
Haemodynamic instability 38.51 19.53 19 7471 11720 90609237
Keratoacanthoma 37.88 19.53 9 7481 590 90620367
Seizure 37.25 19.53 54 7436 152575 90468382
Flat affect 37.04 19.53 11 7479 1700 90619257
Tension 36.13 19.53 13 7477 3669 90617288
Atrioventricular block first degree 34.71 19.53 16 7474 8495 90612462
Atrial flutter 34.07 19.53 17 7473 10741 90610216
Psychomotor retardation 32.80 19.53 13 7477 4776 90616181
Metabolic acidosis 32.79 19.53 31 7459 55645 90565312
Granulocytopenia 32.32 19.53 14 7476 6427 90614530
Acute kidney injury 31.85 19.53 77 7413 320310 90300647
Bundle branch block right 31.17 19.53 13 7477 5440 90615517
Hypotension 31.06 19.53 77 7413 325320 90295637
Electrocardiogram abnormal 28.90 19.53 15 7475 10283 90610674
Coagulation test abnormal 28.90 19.53 8 7482 963 90619994
Coagulation time prolonged 28.64 19.53 9 7481 1681 90619276
Cardiac assistance device user 28.61 19.53 5 7485 68 90620889
Bradykinesia 28.43 19.53 13 7477 6775 90614182
Groin infection 27.87 19.53 7 7483 579 90620378
Drug level increased 27.81 19.53 21 7469 27741 90593216
Pain 27.76 19.53 25 7465 996316 89624641
Angina pectoris 27.35 19.53 24 7466 39136 90581821
Overweight 26.87 19.53 12 7478 5922 90615035
Bundle branch block left 26.57 19.53 13 7477 7872 90613085
Duplicate therapy error 26.13 19.53 5 7485 115 90620842
Product measured potency issue 26.00 19.53 5 7485 118 90620839
Periorbital haematoma 25.61 19.53 7 7483 804 90620153
Ventricular tachycardia 25.44 19.53 19 7471 24689 90596268
Atrioventricular block 25.20 19.53 13 7477 8802 90612155
Suicide attempt 25.01 19.53 31 7459 75368 90545589
Supraventricular tachycardia 24.92 19.53 16 7474 16320 90604637
Product temperature excursion issue 24.87 19.53 7 7483 896 90620061
Myocardial ischaemia 24.79 19.53 15 7475 13799 90607158
Diastolic dysfunction 24.44 19.53 12 7478 7321 90613636
Ischaemic hepatitis 24.21 19.53 9 7481 2784 90618173
Overdose 23.86 19.53 45 7445 157664 90463293
Product prescribing issue 23.48 19.53 12 7478 7967 90612990
N-terminal prohormone brain natriuretic peptide 23.13 19.53 4 7486 51 90620906
Defect conduction intraventricular 22.75 19.53 5 7485 231 90620726
Sinus arrest 22.65 19.53 8 7482 2138 90618819
Anhedonia 22.04 19.53 13 7477 11418 90609539
pH body fluid abnormal 21.53 19.53 4 7486 78 90620879
Gastrointestinal haemorrhage 20.66 19.53 31 7459 90217 90530740
Rhythm idioventricular 20.14 19.53 5 7485 394 90620563
International normalised ratio increased 19.94 19.53 22 7468 47294 90573663
Sleep deficit 19.82 19.53 6 7484 990 90619967
Injection site injury 19.80 19.53 6 7484 993 90619964

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Electrocardiogram QRS complex prolonged 246.29 20.59 68 4909 5755 42610603
Bradycardia 129.76 20.59 95 4882 85389 42530969
Electrocardiogram PR prolongation 98.50 20.59 23 4954 985 42615373
Drug interaction 76.46 20.59 122 4855 266877 42349481
Atrial fibrillation 75.51 20.59 87 4890 139506 42476852
Ventricular tachycardia 65.78 20.59 42 4935 30118 42586240
Facial asymmetry 61.01 20.59 13 4964 364 42615994
Palpitations 46.27 20.59 42 4935 50755 42565603
Haematuria 43.51 20.59 43 4934 57756 42558602
Atrioventricular block first degree 43.00 20.59 19 4958 6472 42609886
Accidental exposure to product by child 42.62 20.59 13 4964 1554 42614804
Neonatal pneumonia 41.86 20.59 8 4969 127 42616231
Ventricular arrhythmia 40.38 20.59 18 4959 6261 42610097
Neonatal hypotension 38.41 20.59 8 4969 200 42616158
Arrhythmia 36.05 20.59 33 4944 40284 42576074
Electrocardiogram QT prolonged 33.01 20.59 34 4943 47911 42568447
Dizziness 32.32 20.59 82 4895 249172 42367186
Leukoplakia oral 28.69 20.59 6 4971 153 42616205
Toxicity to various agents 27.24 20.59 73 4904 229063 42387295
Electrocardiogram abnormal 26.86 20.59 16 4961 10129 42606229
Nodal arrhythmia 26.78 20.59 8 4969 891 42615467
Drug level increased 26.50 20.59 23 4954 26177 42590181
Completed suicide 25.97 20.59 43 4934 96422 42519936
Brugada syndrome 25.53 20.59 8 4969 1045 42615313
Areflexia 24.93 20.59 11 4966 3732 42612626
Speech disorder 24.41 20.59 23 4954 29098 42587260
Brain scan abnormal 24.25 20.59 8 4969 1231 42615127
Respiratory disorder neonatal 24.24 20.59 9 4968 1961 42614397
Cerebral artery thrombosis 24.19 20.59 8 4969 1241 42615117
Dry mouth 23.42 20.59 26 4951 39853 42576505
Accidental overdose 23.03 20.59 22 4955 28308 42588050
Generalised tonic-clonic seizure 22.42 20.59 21 4956 26358 42590000
Bundle branch block right 22.02 20.59 13 4964 8093 42608265
Supraventricular tachycardia 21.53 20.59 15 4962 12393 42603965
Ischaemic stroke 21.44 20.59 19 4958 22214 42594144
Sinus bradycardia 21.31 20.59 16 4961 14837 42601521
Atrial flutter 21.30 20.59 17 4960 17234 42599124
Syncope 21.18 20.59 40 4937 99366 42516992

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Electrocardiogram QRS complex prolonged 413.37 17.48 120 12048 12901 110564230
Drug interaction 292.40 17.48 315 11853 499868 110077263
Atrial fibrillation 248.67 17.48 204 11964 229438 110347693
Bradycardia 243.04 17.48 172 11996 155345 110421786
Sinus bradycardia 104.03 17.48 55 12113 29428 110547703
Arrhythmia 97.20 17.48 72 12096 69503 110507628
Electrocardiogram PR prolongation 95.59 17.48 25 12143 1818 110575313
Toxicity to various agents 91.59 17.48 178 11990 480377 110096754
Ventricular tachycardia 91.38 17.48 61 12107 49948 110527183
Completed suicide 86 17.48 119 12049 242262 110334869
Atrioventricular block first degree 78.49 17.48 36 12132 14189 110562942
Loss of consciousness 73.57 17.48 99 12069 196207 110380924
Palpitations 71.77 17.48 88 12080 159124 110418007
Syncope 71.16 17.48 99 12069 202437 110374694
Nodal arrhythmia 64.29 17.48 19 12149 2165 110574966
Generalised tonic-clonic seizure 64.10 17.48 51 12117 54629 110522502
Cardiac arrest 55.84 17.48 87 12081 196666 110380465
Subarachnoid haemorrhage 53.69 17.48 36 12132 29666 110547465
Bundle branch block right 52.24 17.48 26 12142 12265 110564866
Drug level increased 50.64 17.48 42 12126 47677 110529454
Electrocardiogram abnormal 49.80 17.48 29 12139 18680 110558451
Facial asymmetry 49.55 17.48 13 12155 957 110576174
Enzyme induction 49.37 17.48 9 12159 116 110577015
Keratoacanthoma 48.83 17.48 14 12154 1434 110575697
Hypotension 46.72 17.48 145 12023 523704 110053427
Atrial flutter 45.28 17.48 30 12138 24232 110552899
Electrocardiogram QT prolonged 43.94 17.48 57 12111 108903 110468228
Haematuria 42.52 17.48 49 12119 82956 110494175
Thyroid atrophy 41.30 17.48 9 12159 298 110576833
Ventricular arrhythmia 38.96 17.48 20 12148 10067 110567064
Retro-orbital neoplasm 38.94 17.48 7 12161 83 110577048
Pain 37.70 17.48 30 12138 954925 109622206
Central nervous system haemorrhage 37.66 17.48 9 12159 452 110576679
Neonatal pneumonia 37.62 17.48 6 12162 32 110577099
Seizure 37.30 17.48 78 12090 221107 110356024
Intentional overdose 36.75 17.48 58 12110 132443 110444688
Neonatal hypotension 36.10 17.48 6 12162 43 110577088
Brugada syndrome 34.75 17.48 11 12157 1577 110575554
Accidental exposure to product by child 34.28 17.48 13 12155 3185 110573946
Respiratory disorder neonatal 34.13 17.48 6 12162 62 110577069
Heart rate irregular 33.96 17.48 29 12139 34245 110542886
Atrioventricular block complete 33.11 17.48 23 12145 20059 110557072
Dizziness 33.03 17.48 158 12010 698035 109879096
Bradyarrhythmia 32.05 17.48 14 12154 4920 110572211
Ischaemic stroke 31.21 17.48 30 12138 41233 110535898
Metabolic acidosis 30.95 17.48 46 12122 99698 110477433
Flat affect 29.83 17.48 11 12157 2494 110574637
Transient ischaemic attack 29.82 17.48 36 12132 63946 110513185
Labelled drug-drug interaction medication error 29.45 17.48 25 12143 29277 110547854
Tension 28.48 17.48 13 12155 5065 110572066
Haemodynamic instability 28.22 17.48 22 12146 22866 110554265
Cardiogenic shock 27.94 17.48 33 12135 57305 110519826
Sinus arrest 27.44 17.48 12 12156 4230 110572901
Muscle mass 27.22 17.48 7 12161 476 110576655
Systolic dysfunction 26.97 17.48 12 12156 4403 110572728
Supraventricular tachycardia 26.96 17.48 22 12146 24400 110552731
Brain scan abnormal 26.75 17.48 9 12159 1562 110575569
Cholestatic liver injury 26.69 17.48 14 12154 7362 110569769
Presyncope 25.26 17.48 29 12139 48858 110528273
Myocardial ischaemia 25.26 17.48 22 12146 26662 110550469
Diastolic dysfunction 24.76 17.48 16 12152 12388 110564743
Atrioventricular block 24.75 17.48 18 12150 16859 110560272
Coagulation time prolonged 24.72 17.48 10 12158 2907 110574224
Cardiac assistance device user 24.07 17.48 5 12163 131 110577000
Asthenia 23.75 17.48 143 12025 688856 109888275
Product temperature excursion issue 23.30 17.48 7 12161 844 110576287
Rash 23.24 17.48 34 12134 820930 109756201
Psychomotor retardation 23.21 17.48 13 12155 7779 110569352
Epistaxis 23.17 17.48 47 12121 130325 110446806
Coagulation test abnormal 22.78 17.48 8 12160 1578 110575553
Leukoplakia oral 22.53 17.48 6 12162 468 110576663
Cerebral artery thrombosis 22.39 17.48 8 12160 1660 110575471
Periorbital haematoma 21.97 17.48 7 12161 1025 110576106
Groin infection 21.72 17.48 7 12161 1063 110576068
N-terminal prohormone brain natriuretic peptide 21.08 17.48 4 12164 65 110577066
Cardio-respiratory arrest 20.87 17.48 42 12126 115794 110461337
Rheumatoid arthritis 20.56 17.48 4 12164 299609 110277522
Small for dates baby 20.54 17.48 6 12162 656 110576475
Suicide attempt 20.46 17.48 39 12129 103355 110473776
Defect conduction intraventricular 20.04 17.48 6 12162 715 110576416
Joint swelling 19.97 17.48 12 12156 442833 110134298
Overweight 19.84 17.48 11 12157 6453 110570678
Swelling 19.71 17.48 7 12161 351034 110226097
Granulocytopenia 19.65 17.48 14 12154 12701 110564430
Rhythm idioventricular 19.53 17.48 6 12162 779 110576352
Bundle branch block left 19.48 17.48 14 12154 12874 110564257
Areflexia 19.37 17.48 11 12157 6758 110570373
Bradykinesia 19.31 17.48 13 12155 10775 110566356
Low birth weight baby 19.03 17.48 6 12162 849 110576282
Hepatic enzyme increased 18.71 17.48 6 12162 320886 110256245
Electrocardiogram P wave abnormal 18.68 17.48 5 12163 397 110576734
Rhabdomyolysis 18.60 17.48 41 12127 120360 110456771
Stroke volume increased 18.37 17.48 3 12165 19 110577112
pH body fluid abnormal 18.37 17.48 4 12164 132 110576999
Maternal exposure during pregnancy 18.37 17.48 3 12165 254880 110322251
Ventricular asystole 18.36 17.48 5 12163 424 110576707
Upper gastrointestinal haemorrhage 18.33 17.48 25 12143 50071 110527060
Overdose 18.32 17.48 62 12106 233732 110343399
Duplicate therapy error 18.25 17.48 5 12163 434 110576697
Hypersensitivity 18.14 17.48 11 12157 403987 110173144
Tachycardia 17.67 17.48 60 12108 226585 110350546
Injection site injury 17.52 17.48 6 12162 1098 110576033

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC C01BC03 CARDIOVASCULAR SYSTEM
CARDIAC THERAPY
ANTIARRHYTHMICS, CLASS I AND III
Antiarrhythmics, class Ic
FDA EPC N0000175426 Antiarrhythmic
MeSH PA D000889 Anti-Arrhythmia Agents
MeSH PA D002317 Cardiovascular Agents
MeSH PA D026941 Sodium Channel Blockers
MeSH PA D049990 Membrane Transport Modulators
MeSH PA D061567 Voltage-Gated Sodium Channel Blockers
CHEBI has role CHEBI:35554 cardiovascular drug
CHEBI has role CHEBI:38070 anti-arrhythmia drug

Related Drugs by ATC class:

C01BC Antiarrhythmics, class Ic 4 drugs
encainideethacizineflecainidelorcainide

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Atrial fibrillation indication 49436004 DOID:0060224
Paroxysmal supraventricular tachycardia indication 67198005
Paroxysmal atrial fibrillation indication 282825002
Paroxysmal atrial flutter indication 427665004
Life-Threatening Ventricular Tachycardia indication
Cardioversion of Atrial Fibrillation off-label use
Bronchospasm contraindication 4386001
Bundle branch block contraindication 6374002
Hyperkalemia contraindication 14140009
Agranulocytosis contraindication 17182001 DOID:12987
Myocardial infarction contraindication 22298006 DOID:5844
Torsades de pointes contraindication 31722008
Sick sinus syndrome contraindication 36083008 DOID:13884
Hypokalemia contraindication 43339004
Low blood pressure contraindication 45007003
Chronic heart failure contraindication 48447003
Bradycardia contraindication 48867003
Coronary arteriosclerosis contraindication 53741008 DOID:3393
Cardiogenic shock contraindication 89138009
Kidney disease contraindication 90708001 DOID:557
Myasthenia gravis contraindication 91637004 DOID:437
Prolonged QT interval contraindication 111975006
Structural disorder of heart contraindication 128599005
Atrioventricular block contraindication 233917008 DOID:0050820
Disease of liver contraindication 235856003 DOID:409
Severe chronic obstructive pulmonary disease contraindication 313299006
Myocardial infarction in recovery phase contraindication 418044006
Congenital long QT syndrome contraindication 442917000




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.15 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Sodium channel protein type 5 subunit alpha Ion channel BLOCKER IC50 5.48 CHEMBL CHEMBL
Beta-1 adrenergic receptor GPCR ANTAGONIST Ki 6.69 DRUG MATRIX CHEMBL
Sodium channel subunit beta-1 Ion channel WOMBAT-PK
Sodium channel subunit beta-2 Ion channel WOMBAT-PK
Sodium channel subunit beta-3 Ion channel WOMBAT-PK
Sodium channel subunit beta-4 Ion channel WOMBAT-PK
Sigma non-opioid intracellular receptor 1 Membrane receptor Ki 5.96 DRUG MATRIX
Potassium voltage-gated channel subfamily H member 2 Ion channel IC50 6.10 WOMBAT-PK
Multidrug resistance protein 1 Transporter ED50 7.06 WOMBAT-PK
Sodium-dependent noradrenaline transporter Transporter Ki 5.52 DRUG MATRIX
5-hydroxytryptamine receptor 1A GPCR Ki 6.03 DRUG MATRIX
5-hydroxytryptamine receptor 2A GPCR Ki 6.73 DRUG MATRIX
5-hydroxytryptamine receptor 2B GPCR Ki 7.24 DRUG MATRIX
5-hydroxytryptamine receptor 2C GPCR Ki 6.70 DRUG MATRIX
5-hydroxytryptamine receptor 6 GPCR Ki 6.06 DRUG MATRIX
Aldehyde oxidase Enzyme IC50 5.60 WOMBAT-PK
Beta-3 adrenergic receptor GPCR Ki 6.50 DRUG MATRIX
Sodium-dependent dopamine transporter Transporter Ki 5.83 DRUG MATRIX
Cytochrome P450 2D6 Enzyme IC50 5.34 DRUG MATRIX
Alpha-1D adrenergic receptor GPCR Ki 5.60 DRUG MATRIX
Cytochrome P450 1A2 Enzyme IC50 5.48 DRUG MATRIX
Potassium channel subfamily K member 2 Ion channel IC50 5.12 CHEMBL
Potassium voltage-gated channel subfamily A member 5 Ion channel BLOCKER IC50 4.40 IUPHAR
Potassium channel subfamily K member 3 Ion channel IC50 5.29 CHEMBL
Solute carrier family 22 member 1 Transporter IC50 4.95 CHEMBL
Solute carrier family 22 member 2 Transporter IC50 4.60 WOMBAT-PK
Sulfonylurea receptor 2, Kir6.2 Ion channel IC50 5.66 CHEMBL
Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 Ion channel IC50 4.85 WOMBAT-PK
Nuclear receptor subfamily 2 group E member 1 Nuclear hormone receptor EC50 4.33 CHEMBL
Beta-2 adrenergic receptor GPCR ANTAGONIST Ki 7.44 DRUG MATRIX
Alpha-1B adrenergic receptor GPCR Ki 5.85 DRUG MATRIX
Alpha-1A adrenergic receptor GPCR IC50 5.21 CHEMBL
5-hydroxytryptamine receptor 1A GPCR IC50 5.79 CHEMBL

External reference:

IDSource
4019911 VUID
N0000147996 NUI
D00640 KEGG_DRUG
34183-22-7 SECONDARY_CAS_RN
4019487 VANDF
4019911 VANDF
C0033429 UMLSCUI
CHEBI:63619 CHEBI
CHEMBL631 ChEMBL_ID
CHEMBL1201063 ChEMBL_ID
DB01182 DRUGBANK_ID
D011405 MESH_DESCRIPTOR_UI
4932 PUBCHEM_CID
2561 IUPHAR_LIGAND_ID
3312 INN_ID
68IQX3T69U UNII
203135 RXNORM
40681 MMSL
40682 MMSL
5368 MMSL
d00358 MMSL
003525 NDDF
004487 NDDF
108501006 SNOMEDCT_US
372910007 SNOMEDCT_US
96300001 SNOMEDCT_US
68IQX3T69U INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Propafenone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0832-0740 CAPSULE, EXTENDED RELEASE 225 mg ORAL ANDA 30 sections
Propafenone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0832-0741 CAPSULE, EXTENDED RELEASE 325 mg ORAL ANDA 30 sections
Propafenone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0832-0742 CAPSULE, EXTENDED RELEASE 425 mg ORAL ANDA 30 sections
PROPAFENONE HYDROCHLORIDE Human Prescription Drug Label 1 16571-736 CAPSULE, EXTENDED RELEASE 225 mg ORAL ANDA 30 sections
PROPAFENONE HYDROCHLORIDE Human Prescription Drug Label 1 16571-737 CAPSULE, EXTENDED RELEASE 325 mg ORAL ANDA 30 sections
PROPAFENONE HYDROCHLORIDE Human Prescription Drug Label 1 16571-738 CAPSULE, EXTENDED RELEASE 425 mg ORAL ANDA 30 sections
propafenone hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 16714-825 CAPSULE, EXTENDED RELEASE 225 mg ORAL ANDA 29 sections
propafenone hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 16714-826 CAPSULE, EXTENDED RELEASE 325 mg ORAL ANDA 29 sections
propafenone hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 16714-827 CAPSULE, EXTENDED RELEASE 425 mg ORAL ANDA 29 sections
Propafenone HUMAN PRESCRIPTION DRUG LABEL 1 21695-814 CAPSULE, EXTENDED RELEASE 325 mg ORAL ANDA 21 sections
Propafenone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 50090-1134 TABLET, FILM COATED 225 mg ORAL ANDA 29 sections
Propafenone HCl HUMAN PRESCRIPTION DRUG LABEL 1 50090-2975 TABLET, FILM COATED 225 mg ORAL ANDA 29 sections
Propafenone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 50090-4227 TABLET, COATED 225 mg ORAL ANDA 29 sections
Propafenone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 51407-015 TABLET, COATED 150 mg ORAL ANDA 29 sections
Propafenone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 51407-016 TABLET, COATED 225 mg ORAL ANDA 29 sections
Propafenone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 51407-017 TABLET, COATED 300 mg ORAL ANDA 29 sections
Propafenone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 54868-4770 TABLET, FILM COATED 150 mg ORAL ANDA 24 sections
Propafenone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 54868-5950 TABLET, FILM COATED 225 mg ORAL ANDA 24 sections
PROPAFENONE HYDROCHLORIDE Human Prescription Drug Label 1 59651-256 TABLET, FILM COATED 150 mg ORAL ANDA 29 sections
PROPAFENONE HYDROCHLORIDE Human Prescription Drug Label 1 59651-257 TABLET, FILM COATED 225 mg ORAL ANDA 29 sections
PROPAFENONE HYDROCHLORIDE Human Prescription Drug Label 1 59651-258 TABLET, FILM COATED 300 mg ORAL ANDA 29 sections
Propafenone Hydrochloride Human Prescription Drug Label 1 59651-276 CAPSULE, EXTENDED RELEASE 225 mg ORAL ANDA 29 sections
Propafenone Hydrochloride Human Prescription Drug Label 1 59651-277 CAPSULE, EXTENDED RELEASE 325 mg ORAL ANDA 29 sections
Propafenone Hydrochloride Human Prescription Drug Label 1 59651-278 CAPSULE, EXTENDED RELEASE 425 mg ORAL ANDA 29 sections
Propafenone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 60687-709 TABLET, FILM COATED 150 mg ORAL ANDA 29 sections
PROPAFENONE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 60687-930 TABLET, FILM COATED 150 mg ORAL ANDA 27 sections
PROPAFENONE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 60687-930 TABLET, FILM COATED 150 mg ORAL ANDA 27 sections
Propafenone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 62559-230 TABLET, COATED 150 mg ORAL ANDA 29 sections
Propafenone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 62559-231 TABLET, COATED 225 mg ORAL ANDA 29 sections
Propafenone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 62559-232 TABLET, COATED 300 mg ORAL ANDA 29 sections